Related Experiment Videos
The CD154-CD40 costimulatory pathway in transplantation
Akira Yamada And1, Mohamed H Sayegh
1Laboratory of Immunogenetics and Transplantation, Brigham and Women's Hospital, Transplantation Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Transplantation
|January 26, 2002
Summary
Blocking the CD154-CD40 pathway with antibodies can prolong allograft survival. Combination therapies show promise for tolerance induction, but potential thromboembolic complications require further investigation.
Area of Science:
- Immunology
- Transplantation immunology
Background:
- The CD154-CD40 pathway is crucial for T cell activation in alloimmune responses.
- Anti-CD154 antibody therapy has shown potential in prolonging allograft survival and inducing tolerance.
- Monotherapy with anti-CD154 antibodies is insufficient in stringent transplantation models.
Purpose of the Study:
- To review the efficacy and mechanisms of CD154-CD40 pathway blockade in transplantation.
- To explore combination therapies involving anti-CD154 antibodies.
- To discuss the safety profile, including thromboembolic complications.
Main Methods:
- Review of experimental transplantation models and primate studies.
- Analysis of in vivo mechanisms of CD154 blockade.
- Examination of clinical trial data and reported side effects.
Main Results:
- Anti-CD154 blockade can prolong allograft survival and induce tolerance in some models.
- Combination therapies (e.g., with CTLA4-Ig) demonstrate synergistic effects.
- Mechanisms include T-cell anergy, apoptosis, and regulatory cell induction.
- Thromboembolic complications observed in primates and humans warrant caution.
Conclusions:
- CD154-CD40 pathway blockade is a significant strategy in transplantation immunology.
- Combined therapies offer enhanced efficacy for tolerance induction.
- Safety concerns, particularly thromboembolic events, need careful consideration and further research.